This segment focuses on the research, development, and commercialization of Chimeric Antigen Receptor (CAR) T-cell therapies for various cancers. CBMG utilizes proprietary cell-based technologies to engineer T-cells to target and destroy cancer cells. Research and development activities include identifying and validating novel CAR targets, optimizing CAR design, and conducting preclinical and clinical trials. Technologies employed include genetic modification of T-cells, utilizing viral vectors to introduce CAR genes, and advanced cell culture techniques. Therapeutic areas covered include B-cell malignancies (e.g., lymphoma, multiple myeloma) and solid tumors. The patient impact is significant, offering a potential cure for patients with relapsed or refractory cancers. CBMG's market positioning is strengthened by collaborations with major pharmaceutical companies like Janssen, and the segment has significant growth potential due to the increasing demand for personalized cancer treatments. Regulatory and clinical aspects involve navigating FDA approval processes and conducting rigorous clinical trials to demonstrate safety and efficacy. Partnerships with companies like Janssen are crucial for manufacturing and commercialization.

This segment is dedicated to the development of stem cell therapies for degenerative diseases, particularly focusing on joint diseases like knee osteoarthritis. Research and development efforts involve isolating, characterizing, and expanding human adipose-derived mesenchymal progenitor cells (hAMPCs) for therapeutic use. Technologies include cell culture, cell expansion, and characterization of cell products. The primary therapeutic area is orthopedics, specifically addressing joint damage and pain. The patient impact is focused on improving mobility and reducing pain for individuals suffering from osteoarthritis. CBMG's market positioning is based on its AlloJoin therapy, which is in Phase II clinical trials, and Re-Join, which has completed Phase IIb clinical trials. Future opportunities include expanding the application of stem cell therapies to other degenerative conditions. Regulatory and clinical aspects involve conducting clinical trials to demonstrate safety and efficacy and obtaining regulatory approvals. The company is also exploring partnerships to enhance manufacturing and distribution capabilities.

This segment encompasses the research and development of immunotherapies for cancer, including T-cell therapies with genetically modified, tumor antigen-specific T-cell receptors, and next-generation neoantigen-reactive biomarkers based on tumor-infiltrating lymphocytes (TILs). Research activities include identifying and validating tumor antigens, engineering T-cells to target these antigens, and conducting preclinical and clinical trials. Technologies used include genetic engineering, cell culture, and advanced immunological assays. Therapeutic areas include a range of cancer indications, with a focus on solid tumors. The patient impact is aimed at providing effective treatments for cancers that are resistant to conventional therapies. CBMG's market positioning is enhanced by its proprietary cell-based technologies and collaborations. Future opportunities include expanding the range of cancer indications targeted and developing novel immunotherapeutic approaches. Regulatory and clinical aspects involve navigating FDA approval processes and conducting clinical trials to demonstrate safety and efficacy. The company is actively seeking partnerships to accelerate the development and commercialization of its immuno-oncology programs.